Cordula Stillhart1, Georgios Imanidis, Martin Kuentz. 1. University of Applied Sciences and Arts Northwestern Switzerland, School of Life Sciences, Institute of Pharma Technology, Gründenstrasse 40, 4132, Muttenz, Switzerland.
Abstract
PURPOSE: To determine drug precipitation during in vitro lipolysis of a lipid-based drug delivery system (LBDDS) using Raman spectroscopy as a real-time monitoring technique. A second aim was to describe the kinetics of lipolysis-triggered drug precipitation using a theoretical nucleation and growth model. METHODS: A model LBDDS containing different concentration of fenofibrate was digested in vitro and drug precipitation was determined after ultracentrifugation and nanofiltration (off-line methods), as well as by Raman spectroscopy (in-line method). Subsequently, a theoretical nucleation and growth model was fitted to the obtained drug crystallization profiles by considering the lipolysis-triggered change in drug solubility. RESULTS: Compared with standard off-line measurements, Raman spectroscopy enabled a more robust and highly time-resolved analysis of lipolysis-triggered drug precipitation. Although the formulation was rapidly digested, fenofibrate remained in a supersaturated state for several minutes before beginning to crystallize. The in vitro digestion results were in excellent agreement with the theoretical model (R (2) > 0.976). CONCLUSIONS: The combination of real-time Raman spectroscopy and mathematical modeling provided insights into the kinetics of lipolysis-triggered drug crystallization. This knowledge allows a better biopharmaceutical understanding and will, ultimately, lead to the improved development of lipid-based drug formulations.
PURPOSE: To determine drug precipitation during in vitro lipolysis of a lipid-based drug delivery system (LBDDS) using Raman spectroscopy as a real-time monitoring technique. A second aim was to describe the kinetics of lipolysis-triggered drug precipitation using a theoretical nucleation and growth model. METHODS: A model LBDDS containing different concentration of fenofibrate was digested in vitro and drug precipitation was determined after ultracentrifugation and nanofiltration (off-line methods), as well as by Raman spectroscopy (in-line method). Subsequently, a theoretical nucleation and growth model was fitted to the obtained drug crystallization profiles by considering the lipolysis-triggered change in drug solubility. RESULTS: Compared with standard off-line measurements, Raman spectroscopy enabled a more robust and highly time-resolved analysis of lipolysis-triggered drug precipitation. Although the formulation was rapidly digested, fenofibrate remained in a supersaturated state for several minutes before beginning to crystallize. The in vitro digestion results were in excellent agreement with the theoretical model (R (2) > 0.976). CONCLUSIONS: The combination of real-time Raman spectroscopy and mathematical modeling provided insights into the kinetics of lipolysis-triggered drug crystallization. This knowledge allows a better biopharmaceutical understanding and will, ultimately, lead to the improved development of lipid-based drug formulations.
Authors: Daniel Juenemann; Ekarat Jantratid; Christian Wagner; Christos Reppas; Maria Vertzoni; Jennifer B Dressman Journal: Eur J Pharm Biopharm Date: 2010-11-11 Impact factor: 5.571
Authors: Jan Bevernage; Thomas Forier; Joachim Brouwers; Jan Tack; Pieter Annaert; Patrick Augustijns Journal: Mol Pharm Date: 2011-02-22 Impact factor: 4.939
Authors: Christopher J H Porter; Ann Marie Kaukonen; Agnes Taillardat-Bertschinger; Ben J Boyd; Jacquelyn M O'Connor; Glenn A Edwards; William N Charman Journal: J Pharm Sci Date: 2004-05 Impact factor: 3.534
Authors: Sylvie Fernandez; Vincent Jannin; Jean-David Rodier; Nicolas Ritter; Bruno Mahler; Frédéric Carrière Journal: Biochim Biophys Acta Date: 2007-03-02
Authors: Matthew F Crum; Natalie L Trevaskis; Hywel D Williams; Colin W Pouton; Christopher J H Porter Journal: Pharm Res Date: 2015-12-24 Impact factor: 4.200
Authors: Malinda Salim; Sara J Fraser-Miller; Ka Rlis Be Rziņš; Joshua J Sutton; Gisela Ramirez; Andrew J Clulow; Adrian Hawley; Stéphane Beilles; Keith C Gordon; Ben J Boyd Journal: Mol Pharm Date: 2020-02-03 Impact factor: 4.939
Authors: Nafia F Khan; Malinda Salim; Syaza Y Binte Abu Bakar; Kurt Ristroph; Robert K Prud'homme; Adrian Hawley; Ben J Boyd; Andrew J Clulow Journal: Int J Pharm X Date: 2022-02-09
Authors: Linda C Alskär; Janneke Keemink; Jenny Johannesson; Christopher J H Porter; Christel A S Bergström Journal: Mol Pharm Date: 2018-09-07 Impact factor: 4.939